Without Rebates, Evidence Could Be Key For Formulary Placement

By Rachel Cohrs / April 18, 2019 at 5:55 PM

Information about a drug’s effectiveness compared to alternative treatments could help drug makers argue for formulary placement in a system without rebates, Deloitte’s head of life sciences said.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.